Humanigen, Chime sign manufacturing deal for Covid-19 drug candidate lenzilumab
Under the agreement, Chime Biologics will produce lenzilumab bulk drug substance and drug product for Humanigen for commercial…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 May 21
Under the agreement, Chime Biologics will produce lenzilumab bulk drug substance and drug product for Humanigen for commercial…
17 May 21
The US FDA approval of Empaveli is based on results from the head-to-head Phase 3 PEGASUS study
12 May 21
Lilly will hold exclusive commercialisation rights for any products resulting from the research partnership
12 May 21
The partnership will use the capabilities of Capsigen and Biogen to fast-track the delivery of gene therapies to…
11 May 21
The FDA authorisation is based on data from a pivotal Phase 3 clinical trial, which enrolled 2,260 individuals…
11 May 21
Baricitinib, a once-daily, oral medication was discovered by US-based Incyte and licensed to Eli Lilly
10 May 21
The anti-Covid-19 oral drug has been developed by INMAS, a lab of DRDO, in partnership with Hyderabad-based Dr…
10 May 21
The transaction will provide the combined entity with about $250m to fund its decentralised trial technology platform, expand…
07 May 21
The expansion of the manufacturing capacity will help Lonza to deliver contract manufacturing services that will meet the…
07 May 21
The company will use the funding to develop its CapsidMap platform, which uses AI technology for the design…